Constantinos Tsompos*, Constantinos Panoulis, Konstantinos Toutouzas, Aggeliki Triantafyllou, George Zografos and Apostolos Papalois Pages 24 - 27 ( 4 )
Aim: This study compared the hematopoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G, based on 2 preliminary studies. The provided results on hematocrit levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.Materials and Methods: Hematocrit levels were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G. Results: The first preliminary study of Epo non-significantly increased the hematocrit levels by 0.24%+1.38% (p-value=0.8586). The second preliminary study of U-74389G significantly raised the hematocrit levels by 3.16%+1.33% (p-value=0.0196). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has approximately 12.66-fold higher hematopoietic potency than Epo (p-value=0.0000). Conclusion: The anti-oxidant capacities of U-74389G provide satisfactory acute hematopoietic properties; presenting approximately 12.66-fold hematocrit level rise than epo (p-value=0.0000).
Hypoxia, erythropoietin, U-74389G, hematocrit levels, reoxygenation, cytokine.
Department of Obstetrics & Gynecology, Mesologi County Hospital, Nafpaktou Street, Mesologi 30200, Etoloakarnania, Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Attiki, Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Department of Biologic Chemistry, Athens University, Attiki, Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Attiki